--CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of ...

CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of ...

CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene ...

Live webcasts can be accessed on the investor relations page of CAMP4’s website at A replay of the webcasts will be archived on the CAMP4 website ...

Sherry Gao, Tyler Daniel (pictured) and their coauthors developed a new tool that can simultaneously and independently edit multiple genes and regulate their expression. Influential inventions often ...

Learn about gene expression studies in progressive supranuclear palsy in Mayo Clinic's Precision Medicine in Neurodegeneration Lab led by Nilufer Ertekin-Taner, M.D., Ph.D.

GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance ...